Table 1 bPΔ6-hPAP treatment leads to fewer tumor nodules in a metastatic tumor model

From: Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer

 

PBS

Empty

mPAP

hPAP

Total tumor nodules

8

18

10

4*

Mean tumor burden per mouse (cm2)

7.0

16.8

6.9

1.6**

  1. TRAMP-C2 cells (5 × 105 per mouse) were injected intravenously in the tail vain of C57/BL6 mice (N=8 per group) and lung tumors established as previously described.28 Preliminary studies showed microscopic tumor nodules by day 25 and by day 60 animals showed signs of morbidity. Mice were treated four times with 3 × 107 PFU of bPΔ6-hPAP, bPΔ6-mPAP or bPΔ6-empty, or PBS over a period of 10 days. Animals were killed at day 60 and the number of lung tumor nodules and tumor burden per mouse was analyzed as described previously.28 Animals treated with bPΔ6-hPAP viruses showed significantly fewer tumor nodules when compared with bPΔ6-mPAP or PBS groups (*P=0.02), as well as a decrease in tumor burden (**P=0.03 vs bPΔ6-empty). There was no statistical difference between tumor nodules in the bPΔ6-empty vs PBS groups. Pairwise statistical analysis were performed using Student's t-tests.
Back to article page